Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.

Oncologist · 2018 · PMC5759812 · PMID 28894015

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In the subgroup analysis for OS, including propensity score‐adjustment and propensity score‐matching analysis, regorafenib was a favorable trend of OS in the younger patients, whereas TFTD was in the elderly patients.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.